nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.36485/1561-6274-2026-30-1-20-37BOBKBXnefr-2518Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESТаргетная доставка протективных субстанций с помощью наноразмерных носителей при ишемическом–реперфузионном повреждении почекTargeted delivery of protective substances using nano-sized carriers in ischemic-reperfusion kidney injuryhttps://orcid.org/0000-0002-1896-5703ЧебуркинЮ. В.CheburkinYu. V.

Чебуркин Юрий Владимирович, канд. мед. наук, заведующий НИЛ инфекционных патогенов и биомолекулярных наноструктур

197341, Санкт-Петербург, ул. Аккуратова, д. 2

Тел.: (812) 7025168

Yuri V. Cheburkin, MD, PhD, Head of the Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures

197341, Saint Petersburg, Akkuratova str., 2

Phone: (812) 7025168

cheburkin_yuv@almazovcentre.ruhttps://orcid.org/0009-0006-8744-8482СмирновЕ. А.SmirnovE. A.

Смирнов Евгений Алексеевич, НИЛ инфекционных патогенов и биомолекулярных наноструктур, младший научный сотрудник

197341, Санкт-Петербург, ул. Аккуратова, д. 2

Тел.: (812) 7025168

Evgeny A. Smirnov, Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Junior Researcher

197341, Saint Petersburg, Akkuratova str., 2

Phone: (812) 7025168

sea222777@yandex.ruhttps://orcid.org/0000-0002-8723-8622МурашкоЕ. А.MurashkoE. A.

Мурашко Екатерина Александровна, канд. хим. наук, заведующий НИЛ метаболомного и метаболического профилирования; кафедра химии, ассистент

197341, Санкт-Петербург, ул. Аккуратова, д. 2

Тел.: (812) 7025168

Ekaterina A. Murashko, PhD (Chem.), Head of the Research Laboratory of Metabolomic and Metabolic Profiling; Department of Chemistry, Assistant

197341, Saint Petersburg, Akkuratova str., 2

Phone: (812) 7025168

murashko_ea@almazovcentre.ruhttps://orcid.org/0000-0002-3666-9115КолобовА. А.KolobovA. A.

Колобов Алексей Александрович, канд. биол. наук, лаборатория химии пептидов, ведущий научный сотрудник

188663, Ленинградская обл., Всеволожский мкр-н, г. п. Кузьмоловский, ул. Заводская, д. 6/2, корп. 93

Тел.: (812) 7025168

Alexey A. Kolobov, PhD (Biol.), Laboratory of Peptide Chemistry, Leading Researcher

188663, Leningrad region, Vsevolozhsky district, g.p. Kuzmolovskii, Zavodskaya str., 6/2, bldg. 93

Phone: (812) 7025168

kolobov@hpb-spb.comhttps://orcid.org/0000-0002-8437-1313БондаренкоА. Б.BondarenkoA. B.

Бондаренко Андрей Борисович, НИЛ инфекционных патогенов и биомолекулярных наноструктур, младший научный сотрудник; кафедра медицинской биологии, старший преподаватель

197341, Санкт-Петербург, ул. Аккуратова, д. 2; 194100, Санкт-Петербург, ул. Литовская, д. 2

Тел.: (812) 7025168

Andrey B. Bondarenko, Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Junior Researcher; Department of Medical Biology, Senior Lecturer

197341, Saint Petersburg, Akkuratova str., 2; 194100, Saint Petersburg, Litovskaya str., 2. Saint Petersburg

Phone: (812) 7025168

bondarenko_a_b@almazovcentre.ruhttps://orcid.org/0000-0003-4870-8641СитковН. О.SitkovN. O.

Доц. Ситков Никита Олегович, канд. техн. наук, НИЛ инфекционных патогенов и биомолекулярных наноструктур, ведущий научный сотрудник; кафедра микро- и наноэлектроники

197341, Санкт-Петербург, ул. Аккуратова, д. 2; 197022, Санкт-Петербург, ул. Профессора Попова, д. 5, лит. Ф.

Тел.: (812) 7025168

Nikita O. Sitkov, PhD (Tech.), Research Laboratory of Infectious Pathogens and Biomolecular Nanostructures, Leading Researcher; Department of Micro- and Nanoelectronics, Associate Professor

197341, Saint Petersburg, Akkuratova str., 2; 197022, Russia, Saint Petersburg, Professor Popov str., 5, lit. F.

Phone: (812) 7025168

sitkov_no@almazovcentre.ruhttps://orcid.org/0000-0001-5129-9944ГалагудзаМ. М.GalagudzaM. M.

Проф. Галагудза Михаил Михайлович, д-р мед. наук, чл.-кор. РАН, директор Института экспериментальной медицины; заведующий кафедрой патологической физиологии; главный научный сотрудник

197341, Санкт-Петербург, ул. Аккуратова, д. 2; 198095, Санкт-Петербург, ул. Ивана Черных, д. 31-33, лит. А.

Тел.: (812) 7025168

Professor Mikhail M. Galagudza, MD, PhD, DMedSci, Corresponding Member of the RAS, Director of the Institute of Experimental Medicine; Head of the Department of Pathological Physiology; Principal Researcher

197341, Saint Petersburg, Akkuratova str., 2; 198095, Saint Petersburg, Ivan Chernykh str., 31-33, lit. A

Phone: (812) 7025168

galagudza@almazovcentre.ruНациональный медицинский исследовательский центр им. академика В.А. АлмазоваРоссияAlmazov National Medical Research CenterRussian FederationНациональный медицинский исследовательский центр им. академика В.А. Алмазова; Институт медицинского образованияРоссияAlmazov National Medical Research Center; Institute of Medical EducationRussian FederationНаучно-исследовательский институт гигиены, профпатологии и экологии человекаРоссияResearch Institute of Hygiene, Occupational Pathology and Human EcologyRussian FederationНациональный медицинский исследовательский центр им. академика В.А. Алмазова; Санкт-Петербургский государственный педиатрический медицинский университетРоссияAlmazov National Medical Research Center; Saint Petersburg State Pediatric Medical UniversityRussian FederationНациональный медицинский исследовательский центр им. академика В.А. Алмазова; Санкт-Петербургский государственный электротехнический университет «ЛЭТИ» им. В.И. Ульянова (Ленина)РоссияAlmazov National Medical Research Center; Saint Petersburg Electrotechnical University “LETI” named after V.I. Ulyanov (Lenin)Russian FederationНациональный медицинский исследовательский центр им. академика В.А. Алмазова; Институт аналитического приборостроенияРоссияAlmazov National Medical Research Center; Institute for Analytical Instrumentation; Institute of Medical EducationRussian Federation2026090320263012037Copyright © Чебуркин Ю.В., Смирнов Е.А., Мурашко Е.А., Колобов А.А., Бондаренко А.Б., Ситков Н.О., Галагудза М.М., 20262026Чебуркин Ю.В., Смирнов Е.А., Мурашко Е.А., Колобов А.А., Бондаренко А.Б., Ситков Н.О., Галагудза М.М.Cheburkin Y.V., Smirnov E.A., Murashko E.A., Kolobov A.A., Bondarenko A.B., Sitkov N.O., Galagudza M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/2518

Острое ишемическое–реперфузионное повреждение (ИРП) является основной причиной острого повреждения почек. В экспериментальных исследованиях показано, что выраженность ИРП почечной ткани может быть уменьшена с помощью ряда фармакологических воздействий. При этом успешные попытки переноса этих данных в клиническую практику отсутствуют, в том числе из-за неоптимальных фармакокинетических параметров используемых препаратов, их низкой биодоступности или возникновения побочных эффектов при системном введении. Для решения этих проблем в последние годы ведется разработка систем направленной доставки препаратов при ИРП почки с помощью наноразмерных носителей. Связывание с наночастицами позволяет добиться преимущественного накопления действующего вещества в почках с последующим контролируемым высвобождением. Для активной направленной доставки препаратов в почку при ИРП начинают использоваться платформы, содержащие специфические направляющие лиганды, а также группировки, чувствительные к локальным условиям среды. Наибольшее количество исследований, связанных с разработкой систем направленной доставки препаратов в ткань почки, касается антиоксидантов и противовоспалительных агентов. Перспективы совершенствования систем направленной доставки связаны с активным таргетированием поврежденной ткани почки, в том числе путем использования биоподобных покрытий лекарственных наночастиц на основе мембран клеток крови.

Acute ischemic-reperfusion injury (IRI) is the primary cause of acute kidney injury. Experimental studies have shown that the severity of IRI in renal tissue can be reduced through various pharmacological interventions. However, these data have not been successfully transferred into clinical practice, partly due to the suboptimal pharmacokinetic parameters of the drugs, their low bioavailability, and the occurrence of side effects with systemic administration. To address these issues, systems for the targeted delivery of drugs to the kidneys during IRI using nanoscale carriers have been developed in recent years. Binding to nanoparticles enables preferential accumulation of the active substance in the kidneys, followed by controlled release. For active targeted drug delivery to the kidneys during IRI, platforms containing specific guiding ligands and groups sensitive to local environmental conditions are being used. Most studies related to the development of targeted drug delivery systems for kidney tissue focus on antioxidants and anti-inflammatory agents. Improving targeted delivery systems is linked to actively targeting damaged kidney tissue, including using bio-like coatings on drug nanoparticles based on blood cell membranes.

направленная доставкананочастицыишемияреперфузияпочкаострое повреждение почекнефропротекцияtargeted deliverynanoparticlesischemiareperfusionkidneyacute kidney injurynephroprotectionРабота выполнена в рамках государственного задания ФГБУ «НМИЦ им. В.А. Алмазова» Минздрава России «Разработка метода адресной доставки на основе наноконъюгатов кардио-таргетных пептидов» (рег. №: 124021600063-1).The research was performed at the expense of the state assignment of Almazov National Medical Research Center “Development of a method of targeted delivery based on nanoconjugates of cardio-targeting peptides” (reg. No.: 124021600063-1).ReferencesCase J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013;2013:479730. doi: 10.1155/2013/479730Case J, Khan S, Khalid R, Khan A. Epidemiology of acute kidney injury in the intensive care unit. Crit Care Res Pract 2013;2013:479730. doi: 10.1155/2013/479730Turgut F, Awad AS, Abdel-Rahman EM. Acute Kidney Injury: Medical Causes and Pathogenesis. J Clin Med 2023;12(1):375. doi: 10.3390/jcm12010375Turgut F, Awad AS, Abdel-Rahman EM. Acute Kidney Injury: Medical Causes and Pathogenesis. J Clin Med 2023;12(1):375. doi: 10.3390/jcm12010375Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 2015;4(2):20–27. doi: 10.12861/jrip.2015.06Malek M, Nematbakhsh M. Renal ischemia/reperfusion injury; from pathophysiology to treatment. J Renal Inj Prev 2015;4(2):20–27. doi: 10.12861/jrip.2015.06Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376(1– 2):1–43. doi: 10.1007/s00210-007-0183-5Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376(1– 2):1–43. doi: 10.1007/s00210-007-0183-5Liu D, Du Y, Jin FY et al. Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review. Mol Pharm 2021;18(9):3206–3222. doi: 10.1021/acs.molpharmaceut.1c00511Liu D, Du Y, Jin FY et al. Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review. Mol Pharm 2021;18(9):3206–3222. doi: 10.1021/acs.molpharmaceut.1c00511Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121(11):4210–4221. doi: 10.1172/JCI45161Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011;121(11):4210–4221. doi: 10.1172/JCI45161Lieberthal W, Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol 1998;275(5):F623–F631. doi: 10.1152/ajprenal.1998.275.5.F623Lieberthal W, Nigam SK. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol 1998;275(5):F623–F631. doi: 10.1152/ajprenal.1998.275.5.F623Kim MJ, Oh CJ, Hong CW, Jeon JH. Comprehensive overview of the role of mitochondrial dysfunction in the pathogenesis of acute kidney ischemia-reperfusion injury: a narrative review. J Yeungnam Med Sci 2024;41(2):61–73. doi: 10.12701/jyms.2023.01347Kim MJ, Oh CJ, Hong CW, Jeon JH. Comprehensive overview of the role of mitochondrial dysfunction in the pathogenesis of acute kidney ischemia-reperfusion injury: a narrative review. J Yeungnam Med Sci 2024;41(2):61–73. doi: 10.12701/jyms.2023.01347Li C, Yu Y, Zhu S et al. The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives. Cell Death Discov 2024;10(1):216. doi: 10.1038/s41420-024-01979-4Li C, Yu Y, Zhu S et al. The emerging role of regulated cell death in ischemia and reperfusion-induced acute kidney injury: current evidence and future perspectives. Cell Death Discov 2024;10(1):216. doi: 10.1038/s41420-024-01979-4DeWolf SE, Kasimsetty SG, Hawkes AA et al. DAMPs Released from Injured Renal Tubular Epithelial Cells Activate Innate Immune Signals in Healthy Renal Tubular Epithelial Cells. Transplantation 2022;106(8):1589–1599. doi: 10.1097/TP.0000000000004038DeWolf SE, Kasimsetty SG, Hawkes AA et al. DAMPs Released from Injured Renal Tubular Epithelial Cells Activate Innate Immune Signals in Healthy Renal Tubular Epithelial Cells. Transplantation 2022;106(8):1589–1599. doi: 10.1097/TP.0000000000004038Su X, Liu B, Wang S et al. NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation. Transpl Immunol 2022;75:101718. doi: 10.1016/j.trim.2022.101718Su X, Liu B, Wang S et al. NLRP3 inflammasome: A potential therapeutic target to minimize renal ischemia/reperfusion injury during transplantation. Transpl Immunol 2022;75:101718. doi: 10.1016/j.trim.2022.101718Wahl P, Schoop R, Bilic G et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002;13(6):1517–1526. doi: 10.1097/01.asn.0000017901.77985fWahl P, Schoop R, Bilic G et al. Renal tubular epithelial expression of the costimulatory molecule B7RP-1 (inducible costimulator ligand). J Am Soc Nephrol 2002;13(6):1517–1526. doi: 10.1097/01.asn.0000017901.77985fMatsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387–6392.Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46(12 Pt 1):6387–6392.Gatto MS, Johnson MP, Najahi-Missaoui W. Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges. Life 2024;14(6):672. doi: 10.3390/life14060672Gatto MS, Johnson MP, Najahi-Missaoui W. Targeted Liposomal Drug Delivery: Overview of the Current Applications and Challenges. Life 2024;14(6):672. doi: 10.3390/life14060672Skwarczynski M, Bashiri S, Yuan Y et al. Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents. Antibiotics 2022;11(3):412. doi: 10.3390/antibiotics11030412Skwarczynski M, Bashiri S, Yuan Y et al. Antimicrobial Activity Enhancers: Towards Smart Delivery of Antimicrobial Agents. Antibiotics 2022;11(3):412. doi: 10.3390/antibiotics11030412Korolev D, Shumilo M, Shulmeyster G et al. Hemolytic Activity, Cytotoxicity, and Antimicrobial Effects of Silver Nanoparticles Conjugated with Lincomycin or Cefazolin. Int J Mol Sci 2022;23(22):13709. doi: 10.3390/ijms232213709Korolev D, Shumilo M, Shulmeyster G et al. Hemolytic Activity, Cytotoxicity, and Antimicrobial Effects of Silver Nanoparticles Conjugated with Lincomycin or Cefazolin. Int J Mol Sci 2022;23(22):13709. doi: 10.3390/ijms232213709Galagudza M, Korolev D, Postnov V et al. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine 2012;7:1671–1678. doi: 10.2147/IJN.S29511Galagudza M, Korolev D, Postnov V et al. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles. Int J Nanomedicine 2012;7:1671–1678. doi: 10.2147/IJN.S29511Ren JX, Ma HY, Yin WJ et al. Emerging Targeted Delivery Strategies of Nanosystems for Ischemic Stroke Treatment. Int J Nanomedicine 2025;20:8143–8171. doi: 10.2147/IJN.S519328Ren JX, Ma HY, Yin WJ et al. Emerging Targeted Delivery Strategies of Nanosystems for Ischemic Stroke Treatment. Int J Nanomedicine 2025;20:8143–8171. doi: 10.2147/IJN.S519328Roointan A, Xu R, Corrie S et al. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions. J Am Soc Nephrol 2025;36(3):500–518. doi: 10.1681/ASN.0000000608Roointan A, Xu R, Corrie S et al. Nanotherapeutics in Kidney Disease: Innovations, Challenges, and Future Directions. J Am Soc Nephrol 2025;36(3):500–518. doi: 10.1681/ASN.0000000608Yan S, Na J, Liu X, Wu P. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics 2024;16(2):248. doi: 10.3390/pharmaceutics16020248Yan S, Na J, Liu X, Wu P. Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics 2024;16(2):248. doi: 10.3390/pharmaceutics16020248Xian X, Ren Q, Du H et al. Advances in Homing Peptide Targeted Therapies. Int J Pept Res Ther 2025;31:36. doi: 10.1007/s10989-024-10682-yXian X, Ren Q, Du H et al. Advances in Homing Peptide Targeted Therapies. Int J Pept Res Ther 2025;31:36. doi: 10.1007/s10989-024-10682-yZielonka J, Joseph J, Sikora A et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev 2017;117(15):10043–10120. doi: 10.1021/acs.chemrev.7b00042Zielonka J, Joseph J, Sikora A et al. Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications. Chem Rev 2017;117(15):10043–10120. doi: 10.1021/acs.chemrev.7b00042Zhang S, Zhang X, Gao H et al. Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment. Pharmaceutics 2024;16(4):531. doi: 10.3390/pharmaceutics16040531Zhang S, Zhang X, Gao H et al. Cell Membrane-Coated Biomimetic Nanoparticles in Cancer Treatment. Pharmaceutics 2024;16(4):531. doi: 10.3390/pharmaceutics16040531Liu Z, Liu X, Yang Q et al. Neutrophil membrane-enveloped nanoparticles for the amelioration of renal ischemia-reperfusion injury in mice. Acta Biomater 2020;104:158–166. doi: 10.1016/j.actbio.2020.01.018Liu Z, Liu X, Yang Q et al. Neutrophil membrane-enveloped nanoparticles for the amelioration of renal ischemia-reperfusion injury in mice. Acta Biomater 2020;104:158–166. doi: 10.1016/j.actbio.2020.01.018Wang X, Bai R. Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases. Drug Deliv 2023;30(1):2256495. doi: 10.1080/10717544.2023.2256495Wang X, Bai R. Advances in smart delivery of magnetic field-targeted drugs in cardiovascular diseases. Drug Deliv 2023;30(1):2256495. doi: 10.1080/10717544.2023.2256495Li H, Zhang Y, Shu H et al. Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies. Int J Pharm 2022;613:121412. doi: 10.1016/j.ijpharm.2021.121412Li H, Zhang Y, Shu H et al. Highlights in ultrasound-targeted microbubble destruction-mediated gene/drug delivery strategy for treatment of malignancies. Int J Pharm 2022;613:121412. doi: 10.1016/j.ijpharm.2021.121412Kong Y, Chen X, Liu F et al. Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression. Adv Mater 2024;36(30):e2310731. doi: 10.1002/adma.202310731Kong Y, Chen X, Liu F et al. Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression. Adv Mater 2024;36(30):e2310731. doi: 10.1002/adma.202310731Hauser PV, Chang HM, Yanagawa N, Hamon M. Nanotechnology, Nanomedicine, and the Kidney. Appl Sci 2021;11(16):7187. doi: 10.3390/app11167187Hauser PV, Chang HM, Yanagawa N, Hamon M. Nanotechnology, Nanomedicine, and the Kidney. Appl Sci 2021;11(16):7187. doi: 10.3390/app11167187Wu L, Chen M, Mao H et al. Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes. Int J Mol Med 2017;39(4):851–860. doi: 10.3892/ijmm.2017.2902Wu L, Chen M, Mao H et al. Albumin-based nanoparticles as methylprednisolone carriers for targeted delivery towards the neonatal Fc receptor in glomerular podocytes. Int J Mol Med 2017;39(4):851–860. doi: 10.3892/ijmm.2017.2902Wang J, Poon C, Chin D et al. Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. Nano Res 2018;11:5584–5595. doi: 10.1007/s12274-018-2100-2Wang J, Poon C, Chin D et al. Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. Nano Res 2018;11:5584–5595. doi: 10.1007/s12274-018-2100-2Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 2012;109(8):3137– 3142. doi: 10.1073/pnas.1200718109Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA 2012;109(8):3137– 3142. doi: 10.1073/pnas.1200718109Yang J, Zhang R, Wang F et al. Red blood cell membranecamouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery. J Drug Deliv Sci Tech 2023;86:104693. doi: 10.1016/j.jddst.2023.104693Yang J, Zhang R, Wang F et al. Red blood cell membranecamouflaged prednisolone acetate-loaded PLGA nanoparticles for kidney-targeted drug delivery. J Drug Deliv Sci Tech 2023;86:104693. doi: 10.1016/j.jddst.2023.104693Lee TY, Lu HH, Cheng HT et al. Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis. J Control Release 2023;354:417–428. doi: 10.1016/j.jconrel.2022.12.059Lee TY, Lu HH, Cheng HT et al. Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis. J Control Release 2023;354:417–428. doi: 10.1016/j.jconrel.2022.12.059Williams RM, Shah J, Tian HS et al. Selective Nanoparticle Targeting of the Renal Tubules. Hypertension 2018;71(1):87–94. doi: 10.1161/HYPERTENSIONAHA.117.09843Williams RM, Shah J, Tian HS et al. Selective Nanoparticle Targeting of the Renal Tubules. Hypertension 2018;71(1):87–94. doi: 10.1161/HYPERTENSIONAHA.117.09843Wang J, Masehi-Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci 2017;5(8):1450–1459. doi: 10.1039/c7bm00271hWang J, Masehi-Lano JJ, Chung EJ. Peptide and antibody ligands for renal targeting: nanomedicine strategies for kidney disease. Biomater Sci 2017;5(8):1450–1459. doi: 10.1039/c7bm00271hWischnjow A, Sarko D, Janzer M et al. Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. Bioconjug Chem 2016;27(4):1050–1057. doi: 10.1021/acs.bioconjchem.6b00057Wischnjow A, Sarko D, Janzer M et al. Renal Targeting: Peptide-Based Drug Delivery to Proximal Tubule Cells. Bioconjug Chem 2016;27(4):1050–1057. doi: 10.1021/acs.bioconjchem.6b00057Yoshitomi T, Hirayama A, Nagasaki Y. The ROS scavenging and renal protective effects of pH-responsive nitroxide radicalcontaining nanoparticles. Biomaterials 2011;32(31):8021–8028. doi: 10.1016/j.biomaterials.2011.07.014Yoshitomi T, Hirayama A, Nagasaki Y. The ROS scavenging and renal protective effects of pH-responsive nitroxide radicalcontaining nanoparticles. Biomaterials 2011;32(31):8021–8028. doi: 10.1016/j.biomaterials.2011.07.014Xie D, Xu Y, Jing W et al. Berberine nanoparticles protects tubular epithelial cells from renal ischemia-reperfusion injury. Oncotarget 2017;8(15):24154–24162. doi: 10.18632/oncotarget.16530Xie D, Xu Y, Jing W et al. Berberine nanoparticles protects tubular epithelial cells from renal ischemia-reperfusion injury. Oncotarget 2017;8(15):24154–24162. doi: 10.18632/oncotarget.16530Yan J, Wang Y, Zhang J et al. Rapidly Blocking the Calcium Overload/ROS Production Feedback Loop to Alleviate Acute Kidney Injury via Microenvironment-Responsive BAPTA-AM/BAC Co-Delivery Nanosystem. Small 2023;19(17):e2206936. doi: 10.1002/smll.202206936Yan J, Wang Y, Zhang J et al. Rapidly Blocking the Calcium Overload/ROS Production Feedback Loop to Alleviate Acute Kidney Injury via Microenvironment-Responsive BAPTA-AM/BAC Co-Delivery Nanosystem. Small 2023;19(17):e2206936. doi: 10.1002/smll.202206936Zheng Z, Deng G, Qi C et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress. Int J Nanomedicine 2018;14:215–229. doi: 10.2147/IJN.S184804Zheng Z, Deng G, Qi C et al. Porous Se@SiO2 nanospheres attenuate ischemia/reperfusion (I/R)-induced acute kidney injury (AKI) and inflammation by antioxidative stress. Int J Nanomedicine 2018;14:215–229. doi: 10.2147/IJN.S184804Li J, Duan Q, Wei X et al. Kidney-Targeted Nanoparticles Loaded with the Natural Antioxidant Rosmarinic Acid for Acute Kidney Injury Treatment. Small 2022;18(48):e2204388. doi: 10.1002/smll.202204388Li J, Duan Q, Wei X et al. Kidney-Targeted Nanoparticles Loaded with the Natural Antioxidant Rosmarinic Acid for Acute Kidney Injury Treatment. Small 2022;18(48):e2204388. doi: 10.1002/smll.202204388Hou Y, Lin S, Xia J et al. Alleviation of ischemia-reperfusion induced renal injury by chemically modified SOD2 mRNA delivered via lipid nanoparticles. Mol Ther Nucleic Acids 2023;34:102067. doi: 10.1016/j.omtn.2023.102067Hou Y, Lin S, Xia J et al. Alleviation of ischemia-reperfusion induced renal injury by chemically modified SOD2 mRNA delivered via lipid nanoparticles. Mol Ther Nucleic Acids 2023;34:102067. doi: 10.1016/j.omtn.2023.102067Zhang J, Ren X, Nie Z et al. Dual-responsive renal injury cells targeting nanoparticles for vitamin E delivery to treat ischemia reperfusion-induced acute kidney injury. J Nanobiotechnology 2024;22(1):626. doi: 10.1186/s12951-024-02894-7Zhang J, Ren X, Nie Z et al. Dual-responsive renal injury cells targeting nanoparticles for vitamin E delivery to treat ischemia reperfusion-induced acute kidney injury. J Nanobiotechnology 2024;22(1):626. doi: 10.1186/s12951-024-02894-7Zuo Z, Luo M, Liu Z et al. Selenium nanoparticles alleviate renal ischemia/reperfusion injury by inhibiting ferritinophagy via the XBP1/NCOA4 pathway. Cell Commun Signal 2024;22(1):376. doi: 10.1186/s12964-024-01751-2Zuo Z, Luo M, Liu Z et al. Selenium nanoparticles alleviate renal ischemia/reperfusion injury by inhibiting ferritinophagy via the XBP1/NCOA4 pathway. Cell Commun Signal 2024;22(1):376. doi: 10.1186/s12964-024-01751-2Zhou L, Tang S, Li F et al. Ceria nanoparticles prophylactic used for renal ischemia-reperfusion injury treatment by attenuating oxidative stress and inflammatory response. Biomaterials 2022;287:121686. doi: 10.1016/j.biomaterials.2022.121686Zhou L, Tang S, Li F et al. Ceria nanoparticles prophylactic used for renal ischemia-reperfusion injury treatment by attenuating oxidative stress and inflammatory response. Biomaterials 2022;287:121686. doi: 10.1016/j.biomaterials.2022.121686Saleh H, Salama M, Hussein RM. Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia-reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway. Environ Sci Pollut Res Int 2022;29(51):77884–77907. doi: 10.1007/s11356-022-21235-5Saleh H, Salama M, Hussein RM. Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia-reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway. Environ Sci Pollut Res Int 2022;29(51):77884–77907. doi: 10.1007/s11356-022-21235-5Huang ZW, Shi Y, Zhai YY et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury. J Control Release 2021;334:275–289. doi: 10.1016/j.jconrel.2021.04.033Huang ZW, Shi Y, Zhai YY et al. Hyaluronic acid coated bilirubin nanoparticles attenuate ischemia reperfusion-induced acute kidney injury. J Control Release 2021;334:275–289. doi: 10.1016/j.jconrel.2021.04.033Qin S, Wu B, Gong T et al. Targeted delivery via albumin corona nanocomplex to renal tubules to alleviate acute kidney injury. J Control Release 2022;349:401–412. doi: 10.1016/j.jconrel.2022.07.013Qin S, Wu B, Gong T et al. Targeted delivery via albumin corona nanocomplex to renal tubules to alleviate acute kidney injury. J Control Release 2022;349:401–412. doi: 10.1016/j.jconrel.2022.07.013Zhang J, Xie H, Wang T et al. Epicatechin-assembled nanoparticles against renal ischemia/reperfusion injury. J Mater Chem B 2022;10(36):6965–6973. doi: 10.1039/d2tb01301kZhang J, Xie H, Wang T et al. Epicatechin-assembled nanoparticles against renal ischemia/reperfusion injury. J Mater Chem B 2022;10(36):6965–6973. doi: 10.1039/d2tb01301kWang N, Xue X, Zhang Z et al. Curcumin-loaded nanoparticles for renal ischemia-reperfusion injuries: Triple-play of redox homeostasis accommodation, lipid metabolism regulation, and nuclear magnetic tracing. Mater Today Bio 2025;33:101986. doi: 10.1016/j.mtbio.2025.101986Wang N, Xue X, Zhang Z et al. Curcumin-loaded nanoparticles for renal ischemia-reperfusion injuries: Triple-play of redox homeostasis accommodation, lipid metabolism regulation, and nuclear magnetic tracing. Mater Today Bio 2025;33:101986. doi: 10.1016/j.mtbio.2025.101986Han SJ, Williams RM, D’Agati V et al. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int 2020;98(1):76–87. doi: 10.1016/j.kint.2020.01.036Han SJ, Williams RM, D’Agati V et al. Selective nanoparticle-mediated targeting of renal tubular Toll-like receptor 9 attenuates ischemic acute kidney injury. Kidney Int 2020;98(1):76–87. doi: 10.1016/j.kint.2020.01.036Shen Y, Yang F, Wu F et al. STING antagonist-loaded renal tubule epithelial cell-mimicking nanoparticles ameliorate acute kidney injury by orchestrating innate and adaptive immunity. Nano Today 2024;55:102209. doi: 10.1016/j.nantod.2024.102209Shen Y, Yang F, Wu F et al. STING antagonist-loaded renal tubule epithelial cell-mimicking nanoparticles ameliorate acute kidney injury by orchestrating innate and adaptive immunity. Nano Today 2024;55:102209. doi: 10.1016/j.nantod.2024.102209Kim S, Jo H, Lee S et al. Targeted echogenic and antiinflammatory polymeric prodrug nanoparticles for the management of renal ischemia/reperfusion injury. J Control Release 2023;363:574–584. doi: 10.1016/j.jconrel.2023.10.004Kim S, Jo H, Lee S et al. Targeted echogenic and antiinflammatory polymeric prodrug nanoparticles for the management of renal ischemia/reperfusion injury. J Control Release 2023;363:574–584. doi: 10.1016/j.jconrel.2023.10.004Shin H, Jeong S, Lee Y et al. H2O2-Activatable Antioxidant Polymeric Prodrug Nanoparticles for the Prevention of Renal Ischemia/Reperfusion Injury. Biomacromolecules 2022;23(9):3810– 3821. doi: 10.1021/acs.biomac.2c00669Shin H, Jeong S, Lee Y et al. H2O2-Activatable Antioxidant Polymeric Prodrug Nanoparticles for the Prevention of Renal Ischemia/Reperfusion Injury. Biomacromolecules 2022;23(9):3810– 3821. doi: 10.1021/acs.biomac.2c00669Guo L, Wang H, Liu X et al. Prolonged Retention of Albumin Nanoparticles Alleviates Renal Ischemia-Reperfusion Injury through Targeted Pyroptosis. ACS Appl Mater Interfaces 2024;16(44):59921–59933. doi: 10.1021/acsami.4c13481Guo L, Wang H, Liu X et al. Prolonged Retention of Albumin Nanoparticles Alleviates Renal Ischemia-Reperfusion Injury through Targeted Pyroptosis. ACS Appl Mater Interfaces 2024;16(44):59921–59933. doi: 10.1021/acsami.4c13481Xu L, Xing Z, Yuan J et al. Ultrasmall Nanoparticles Regulate Immune Microenvironment by Activating IL-33/ST2 to Alleviate Renal Ischemia-Reperfusion Injury. Adv Healthc Mater 2024;13(13):e2303276. doi: 10.1002/adhm.202303276Xu L, Xing Z, Yuan J et al. Ultrasmall Nanoparticles Regulate Immune Microenvironment by Activating IL-33/ST2 to Alleviate Renal Ischemia-Reperfusion Injury. Adv Healthc Mater 2024;13(13):e2303276. doi: 10.1002/adhm.202303276Karimi Z, Asadi K, Ghahramani P, Gholami A. Trinitroglycerine-loaded chitosan nanoparticles attenuate renal ischemia-reperfusion injury by modulating oxidative stress. Sci Rep 2024;14(1):32112. doi: 10.1038/s41598-024-83886-3Karimi Z, Asadi K, Ghahramani P, Gholami A. Trinitroglycerine-loaded chitosan nanoparticles attenuate renal ischemia-reperfusion injury by modulating oxidative stress. Sci Rep 2024;14(1):32112. doi: 10.1038/s41598-024-83886-3Chen J, Vemuri C, Palekar RU et al. Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury. Am J Physiol Renal Physiol 2015;308(7):F765–F773. doi: 10.1152/ajprenal.00457.2014Chen J, Vemuri C, Palekar RU et al. Antithrombin nanoparticles improve kidney reperfusion and protect kidney function after ischemia-reperfusion injury. Am J Physiol Renal Physiol 2015;308(7):F765–F773. doi: 10.1152/ajprenal.00457.2014Vallorz EL, Janda J, Mansour HM, Schnellmann RG. Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney Int 2022;102(5):1073–1089. doi: 10.1016/j.kint.2022.05.032Vallorz EL, Janda J, Mansour HM, Schnellmann RG. Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney Int 2022;102(5):1073–1089. doi: 10.1016/j.kint.2022.05.032Xie D, Wang J, Hu G et al. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury. J Pharmacol Exp Ther 2021;378(3):235–243. doi: 10.1124/jpet.121.000667Xie D, Wang J, Hu G et al. Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury. J Pharmacol Exp Ther 2021;378(3):235–243. doi: 10.1124/jpet.121.000667Jiang W, Hou X, Qi Y et al. pH-Activatable Pre-Nanozyme Mediated H2S Delivery for Endo-Exogenous Regulation of Oxidative Stress in Acute Kidney Injury. Adv Sci 2024;11(18):e2303901. doi: 10.1002/advs.202303901Jiang W, Hou X, Qi Y et al. pH-Activatable Pre-Nanozyme Mediated H2S Delivery for Endo-Exogenous Regulation of Oxidative Stress in Acute Kidney Injury. Adv Sci 2024;11(18):e2303901. doi: 10.1002/advs.202303901Embaby EM, Saleh RM, Marghani BH et al. The combined effect of zinc oxide nanoparticles and milrinone on acute renal ischemia/reperfusion injury in rats: Potential underlying mechanisms. Life Sci 2023;323:121435. doi: 10.1016/j.lfs.2023.121435Embaby EM, Saleh RM, Marghani BH et al. The combined effect of zinc oxide nanoparticles and milrinone on acute renal ischemia/reperfusion injury in rats: Potential underlying mechanisms. Life Sci 2023;323:121435. doi: 10.1016/j.lfs.2023.121435Xu M, Zhao M, Zheng D. Effect of IGF-1C domain-modified nanoparticles on renal ischemia-reperfusion injury in mice. Ren Fail 2022;44(1):1376–1387. doi: 10.1080/0886022X.2022.2098773Xu M, Zhao M, Zheng D. Effect of IGF-1C domain-modified nanoparticles on renal ischemia-reperfusion injury in mice. Ren Fail 2022;44(1):1376–1387. doi: 10.1080/0886022X.2022.2098773Zhang R, Zhang X, Zhu X et al. Nanoparticles transfected with plasmid-encoded lncRNA-OIP5-AS1 inhibit renal ischemiareperfusion injury in mice via the miR-410-3p/Nrf2 axis. Ren Fail 2024;46(1):2319327. doi: 10.1080/0886022X.2024.2319327Zhang R, Zhang X, Zhu X et al. Nanoparticles transfected with plasmid-encoded lncRNA-OIP5-AS1 inhibit renal ischemiareperfusion injury in mice via the miR-410-3p/Nrf2 axis. Ren Fail 2024;46(1):2319327. doi: 10.1080/0886022X.2024.2319327Hou Y, Xin Y, Liu S et al. A biocompatible nanoparticlebased approach to inhibiting renal ischemia reperfusion injury in mice by blocking thrombospondin-1 activity. Am J Transplant 2022;22(9):2246–2253. doi: 10.1111/ajt.17052Hou Y, Xin Y, Liu S et al. A biocompatible nanoparticlebased approach to inhibiting renal ischemia reperfusion injury in mice by blocking thrombospondin-1 activity. Am J Transplant 2022;22(9):2246–2253. doi: 10.1111/ajt.17052

The authors declare that there are no conflicts of interest present.